Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Human Metabolome Technologies, Inc. (6090.T)
Tsuruoka, JP
Human Metabolome Technologies, Inc. is a biotechnology company based in Tsuruoka, Japan, established in 2003. It focuses on developing and providing metabolomics technologies and solutions for a range of applications, including drug discovery, disease diagnosis, and food production primarily within Japan. The company offers a comprehensive suite of metabolome analysis services, encompassing global profiling, targeted assays, flux analysis, and lipidomics. Additionally, it develops biomarkers, such as Phosphorylethanolamine, which is measured in blood plasma as a marker for major depressive disorder. HMT's solutions address diverse areas like cancer metabolism, infectious diseases, basic and clinical research, food and nutrition, and microbiome studies. The company also fosters collaborations, notably with the Institute for Advanced Biosciences and Keio University, to further advance metabolome analysis technology.
No mergers or acquisitions recorded for this company.
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| -0.31% | -7.14% | -10.03% | -10.41% | -3.19% | -4.93% | -6.87% | -11.40% | -19.67% | -23.25% | -77.59% |
Revenue flow
Revenue by geography
Revenue by segment
Revenue composition
By product
By geography
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.
| Rating | 2024-11 | Change |
|---|---|---|
| Strong Buy | 0 | 0 |
| Buy | 0 | 0 |
| Hold | 0 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
-
Revenue growth Medical - Diagnostics & Research: +7.9%+8.1% ★ Q1'26: -23.0% (vs Q1'25)
-
EPS growth Medical - Diagnostics & Research: +30.8%+6.0% Q1'26: -39.5% (vs Q1'25)
-
FCF margin FCF growth · Medical - Diagnostics & Research: +32.2%+20.4% ★ Q1'26: +0.0% (vs Q1'25)
-
EBIT margin Medical - Diagnostics & Research: +9.6%+17.2% ★ Q1'26: +36.1% (vs Q1'25)
-
ROIC Medical - Diagnostics & Research: +5.2%+56.0% ★ Q1'26: +91.1% (vs Q1'25)
-
Share dilution Medical - Diagnostics & Research: 0.0%-0.7% ★ Q1'26: -4.6% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Medical - Diagnostics & Research: -0.13×0.31× ★ Q1'26: 0.14× (vs Q1'25)
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
| Metric |
Jun 2014 actual |
Jun 2015 actual |
Jun 2016 actual |
Jun 2017 actual |
Jun 2018 actual |
Jun 2019 actual |
Jun 2020 actual |
Jun 2021 actual |
Jun 2022 actual |
Jun 2023 actual |
Jun 2024 actual |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue |
780.00M
est.
|
780.00M
est.
|
770.00M
est.
|
800.00M
est.
|
990.00M
est.
|
900.00M
est.
|
1.12B
est: 1.11B (+0.8%)
|
1.12B
est: 1.25B (-10.1%)
|
1.22B
est: 1.20B (+1.9%)
|
1.30B
est: 1.30B (-0.1%)
|
1.35B
est: 1.40B (-3.9%)
|
| EBITDA |
173.83M
est.
|
173.83M
est.
|
171.60M
est.
|
178.29M
est.
|
220.63M
est.
|
200.58M
est.
|
23.84M
est: 247.38M (-90.4%)
|
108.33M
est: 278.58M (-61.1%)
|
329.02M
est: 267.44M (+23.0%)
|
319.65M
est: 289.72M (+10.3%)
|
350.31M
est: 506.02M (-30.8%)
|
| EBIT |
127.10M
est.
|
127.10M
est.
|
125.48M
est.
|
130.36M
est.
|
161.33M
est.
|
146.66M
est.
|
-24.12M
est: 180.88M (-113.3%)
|
52.49M
est: 203.69M (-74.2%)
|
264.13M
est: 195.55M (+35.1%)
|
239.27M
est: 211.84M (+12.9%)
|
264.00M
est: 380.14M (-30.6%)
|
| Net Income |
33.47M
est.
|
33.47M
est.
|
-88.09M
est.
|
-271.89M
est.
|
-167.66M
est.
|
-502.08M
est.
|
-47.79M
est: -49.91M (+4.2%)
|
58.21M
est: 49.91M (+16.6%)
|
267.79M
est: 148.57M (+80.2%)
|
285.76M
est: 159.14M (+79.6%)
|
243.25M
est: 199.07M (+22.2%)
|
| SGA |
333.64M
est.
|
333.64M
est.
|
329.36M
est.
|
342.19M
est.
|
423.46M
est.
|
384.97M
est.
|
718.00M
est: 474.79M (+51.2%)
|
663.00M
est: 534.67M (+24.0%)
|
486.00M
est: 513.29M (-5.3%)
|
454.00M
est: 556.06M (-18.4%)
|
457.91M
est: 598.83M (-23.5%)
|
| EPS |
5.70
est.
|
5.70
est.
|
-15.00
est.
|
-46.30
est.
|
-28.55
est.
|
-85.50
est.
|
-8.15
est: -8.50 (+4.1%)
|
9.87
est: 8.50 (+16.1%)
|
45.39
est: 25.30 (+79.4%)
|
48.39
est: 27.10 (+78.6%)
|
41.14
est: 33.90 (+21.4%)
|
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-11 | A | 4/5 | 5/5 | 4/5 | 5/5 | 3/5 | 3/5 | 3/5 |
| 2026-05-08 | A | 4/5 | 5/5 | 4/5 | 5/5 | 3/5 | 3/5 | 3/5 |
| 2026-05-07 | A | 4/5 | 5/5 | 4/5 | 5/5 | 3/5 | 3/5 | 3/5 |
| 2026-05-01 | A | 4/5 | 5/5 | 4/5 | 5/5 | 3/5 | 3/5 | 3/5 |
| 2026-04-30 | A | 4/5 | 5/5 | 4/5 | 5/5 | 3/5 | 3/5 | 3/5 |
| 2026-04-28 | A | 4/5 | 5/5 | 4/5 | 5/5 | 2/5 | 3/5 | 3/5 |
| 2026-04-27 | A | 4/5 | 5/5 | 4/5 | 5/5 | 2/5 | 3/5 | 3/5 |
| 2026-04-24 | A | 4/5 | 5/5 | 4/5 | 5/5 | 2/5 | 3/5 | 3/5 |
| 2026-04-23 | A | 4/5 | 5/5 | 4/5 | 5/5 | 2/5 | 3/5 | 3/5 |
| 2026-04-22 | A | 4/5 | 5/5 | 4/5 | 5/5 | 2/5 | 3/5 | 3/5 |
| 2026-04-21 | A | 4/5 | 5/5 | 4/5 | 5/5 | 2/5 | 3/5 | 3/5 |
| 2026-04-20 | A | 4/5 | 5/5 | 4/5 | 5/5 | 2/5 | 3/5 | 3/5 |
| 2026-04-17 | A | 4/5 | 5/5 | 4/5 | 5/5 | 2/5 | 3/5 | 3/5 |
| 2026-04-16 | A | 4/5 | 5/5 | 4/5 | 5/5 | 2/5 | 3/5 | 3/5 |
Owner Earnings
Ownership Overview
Ownership breakdown not available.
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional history not available.
Top holders not available.
ETF Ownership
This company is not held by any ETF in our universe.
Insider Activity
No insider activity available.
Insider history not available.
No recent insider transactions.
Executive team
Executive compensation
Executive compensation not available.
No CEO compensation history available.
Proxy statements
No proxy statements available for this company yet.
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Atsushi Nagashima | Executive Officer & GM of Information System Department | — | — |
| Jun Nagashima | Chief Information Officer & Executive Officer | — | — |
| Kazuyoshi Sasaki | Chief Innovation Officer & Executive Officer | — | — |
| Kenjiro Kami | Chief Operating Officer, GM of Business Management Division & Director | — | male |
| Masaru Tomita | Co-Founder and Member of Technical Advisory Board | — | male |
| Naotaka Kametani | Executive Officer & Chief Alliance Officer | — | — |
| Tomoyoshi Soga | Co-Founder and Member of Technical Advisory Board | — | — |
| Yasuhiro Ohata | President, Chief Financial Officer & Chairman | — | male |
No data available for this company.
No Senate trading activity found for this company.
No House trading activity found for this company.
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for 6090.T
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
